04.12.2024 • NewsSanofiInsulininvestment

Sanofi to Invest $1 Billion in New Insulin Manufacturing Site in China

Sanofi plans to invest around €1 billion ($1.1 billion) in the construction of a new insulin production facility in Beijing – the company's largest single investment in China to date. This was reported by Reuters and other news agencies.

With the new plant, to be located in the Beijing Economic and Technological Development Zone, the Paris-based French drugmaker wants to significantly expand its production capacity in Asia, the company explained via the Chinese messaging service WeChat. The new plant will allow Sanofi to focus more on the needs of local diabetes patients.

The new production facility would be the company's second site in the Chinese capital Beijing and the fourth in the whole of China.

Beijing is currently courting foreign companies to strengthen their local presence, as international investment in China has declined in recent years.

At a meeting with Frederic Oudea, chairman of the Sanofi board of directors, in Beijing on Monday, Chinese Commerce Minister Wang Wentao said China will support all businesses equally in technological innovation and participating in market competition, as a ministry statement said.

China will continue to open up its market, and is committed to building a business environment for companies including Sanofi to operate and develop with "peace of mind," Wang added according to Reuters.

© Shutterstock / Media
© Shutterstock / Media

Company

Logo:

Sanofi S.A.

46-48 Avenue de la Grande Armée
Paris
France

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.